Detroit voters approved a ballot initiative to widely decriminalize psychedelics, making it the latest in a growing number of jurisdictions to enact the reform.
Exploring the companies and themes that make up this emerging and exciting new sector
Compass Pathways 2.0: A New Rally In Psychedelic Stocks?
Compass Pathways lifted the whole sector in 2020. With CMPS again rising, is history about to repeat?
Red Light Holland Appoints New Chief Financial Officer
Red Light Holland appoints a new Chief Financial Officer, David Ascott.
MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022
MINDCURE announces its Q1 fiscal 2022 results, including initial release of its iSTRYM platform. Cash and equivalents of CAD$15.6 million as of August 31, 2021.
Psychedelics Clinics Race Gaining Momentum
The rapidly expanding networks of psychedelics-based treatment clinics is a horse race where EVERYONE is a winner.
Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology
Cybin receives IND authorization from the FDA to study ketamine's psychedelic effect on the cerebral cortex.
MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program
MindMed announces a new R&D initiative focused on an MDMA derivative, and aimed at treating social anxiety.
The Psychedelics Revolution is EVERYWHERE
Psychedelic drugs are all over the news. Not just general news but also business media. Big news. Big Business.
Levitee Labs Enters into Credit Facility For Up To $12 Million
Levitee Labs announces new credit facility for up to CAD$12 million to finance expansion of its clinics network.
Psychedelics Industry Moving Full-Speed Ahead, When Will Stocks Catch Up?
Cash-rich psychedelic stocks are cheap. They are also building value for investors -- at an accelerating rate.
Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder
The UK drug regulator (MHRS) has granted Small Pharma Fast-Track Designation with respect to SPL026 for Major Depressive Disorder (MDD).